(Q35557394)

8 August 2017

1 reference

title

Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents (English)

1 reference

8 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02847-2

20 March 2024

author name string

Ronald A. Greenfield

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14554016

20 March 2024

Michael S. Bronze

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14554016

20 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14554016

20 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1359644603028472?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02847-2

https://api.elsevier.com/content/article/PII:S1359644603028472?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02847-2

20 March 2024

1 reference

8 August 2017

8

1 reference

8 August 2017

19

1 reference

8 August 2017

881-888

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

8 August 2017

1 reference

7 January 2021

Management of anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Bacillus anthracis and antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Antimicrobial therapy for bacillus anthracis-induced polymicrobial infection in (60)Co gamma-irradiated mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Anti-inflammatory strategies for the treatment of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Postexposure prophylaxis against experimental inhalation anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Passive antibody administration (immediate immunity) as a specific defense against biological weapons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Designing a polyvalent inhibitor of anthrax toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

A bacteriolytic agent that detects and kills Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Field Evaluation of a Human Anthrax Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Observations on the prophylaxis of experimental pulmonary anthrax in the monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Prevention of inhalational anthrax in the U.S. outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

In vitro antimicrobial susceptibilities of strains of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Plague. A clinical review of 27 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

The efficacy of ciprofloxacin and doxycycline against experimental tularaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Multidrug resistance in Yersinia pestis mediated by a transferable plasmid

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Plague vaccine research and development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

1 reference

7 January 2021

Tularemia epidemic in northwestern Spain: clinical description and therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Membrane proteins of Francisella tularensis LVS differ in ability to induce proliferation of lymphocytes from tularemia-vaccinated individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Development of vaccines for prevention of botulism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902847-2

7 January 2021

Tularemia as a biological weapon

series ordinal

46

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02847-2

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference